Neurology 2002;59:1844-1850
© 2002 American Academy of Neurology
Views & Reviews
Thymoma in patients with MG
Characteristics and long-term outcome
A. Evoli, MD,
C. Minisci, MD,
C. Di Schino, MD,
F. Marsili, MD,
C. Punzi, MD,
A. P. Batocchi, MD PhD,
P. A. Tonali, MD,
G. B. Doglietto, MD,
P. Granone, MD,
L. Trodella, MD,
A. Cassano, MD and
L. Lauriola, MD
From the Institutes of Neurology (Drs. Evoli, Minisci, Di Schino, Marsili, Punzi, Batocchi, and Tonali), Surgery (Drs. Doglietto and Granone), Radiology (Dr. Trodella), Internal Medicine (Dr. Cassano), and Pathology (Dr. Lauriola), Catholic University, Rome, Italy.
Address correspondence and reprint requests to Dr. Amelia Evoli, Institute of Neurology, Catholic University, L.go F. Vito, 1-00168 Rome, Italy; e-mail: a.evoli{at}rm.unicatt.it
Objective: To examine the characteristics of thymoma when associated with MG and to evaluate those conditions that can complicate management and affect survival.
Methods: The study includes 207 myasthenic patients who were operated on for thymoma, with at least 1-year follow-up from surgery. MG severity and response to treatment, the occurrence of paraneoplastic diseases and extrathymic malignancies, thymoma histologic types and stages, adjuvant therapy, tumor recurrences, and causes of death were recorded.
Results: MG-associated thymoma was predominantly of B type and was invasive in the majority of patients. MG was generally severe, and most patients remained dependent on immunosuppressive therapy. Other paraneoplastic disorders and extrathymic malignancies were found in 9.66 and 11.11% of patients. Thymoma recurrences occurred in 18 of 115 patients with invasive tumors (15.65%) and were often associated with the onset/aggravation of autoimmune diseases. On completion of the study, MG and thymoma accounted for a similar mortality rate.
Conclusions: Thymoma should be considered as a potentially malignant tumor requiring prolonged follow-up. The presence of myasthenic weakness can still complicate its management. Thymoma-related deaths are bound to outnumber those due to MG in the future.
This article has been cited by other articles:
|
|
|
|
 
S. Margaritora, A. Cesario, G. Cusumano, E. Meacci, R. D'Angelillo, S. Bonassi, G. Carnassale, V. Porziella, A. Tessitore, M. L. Vita, et al.
Thirty-Five-Year Follow-Up Analysis of Clinical and Pathologic Outcomes of Thymoma Surgery.
Ann. Thorac. Surg.,
January 1, 2010;
89(1):
245 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Suzuki, K. Utsugisawa, H. Yoshikawa, M. Motomura, S. Matsubara, K. Yokoyama, Y. Nagane, T. Maruta, T. Satoh, H. Sato, et al.
Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Arch Neurol,
November 1, 2009;
66(11):
1334 - 1338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tomaszek, D. A. Wigle, S. Keshavjee, and S. Fischer
Thymomas: Review of Current Clinical Practice.
Ann. Thorac. Surg.,
June 1, 2009;
87(6):
1973 - 1980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lucchi, R. Ricciardi, F. Melfi, L. Duranti, F. Basolo, G. Palmiero, L. Murri, and A. Mussi
Association of thymoma and myasthenia gravis: oncological and neurological results of the surgical treatment
Eur. J. Cardiothorac. Surg.,
May 1, 2009;
35(5):
812 - 816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Davenport and R. A. Malthaner
The Role of Surgery in the Management of Thymoma: A Systematic Review
Ann. Thorac. Surg.,
August 1, 2008;
86(2):
673 - 684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J F Owe, A K Daltveit, and N E Gilhus
Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001
J. Neurol. Neurosurg. Psychiatry,
February 1, 2006;
77(2):
203 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-S. Hsu, C.-S. Huang, B.-S. Huang, H.-C. Lee, K.-P. Kao, W.-H. Hsu, and M.-H. Huang
Thymoma is associated with relapse of symptoms after transsternal thymectomy for myasthenia gravis
Interactive CardioVascular and Thoracic Surgery,
February 1, 2006;
5(1):
42 - 46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Saka, M. A. Topcuoglu, B. Akkaya, A. Galati, M. Z. Onal, A. Vincent, A. Evoli, and L. Lauriola
Thymus changes in anti-MuSK-positive and -negative myasthenia gravis
Neurology,
September 13, 2005;
65(5):
782 - 783.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Zisis, D. Rontogianni, C. Tzavara, K. Stefanaki, A. Chatzimichalis, A. Loutsidis, K. Iliadis, A. Kontaxis, T. Dosios, and I. Bellenis
Prognostic Factors in Thymic Epithelial Tumors Undergoing Complete Resection
Ann. Thorac. Surg.,
September 1, 2005;
80(3):
1056 - 1062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Romi, G. O. Skeie, N. E. Gilhus, and J. A. Aarli
Striational Antibodies in Myasthenia Gravis: Reactivity and Possible Clinical Significance
Arch Neurol,
March 1, 2005;
62(3):
442 - 446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
